title: How Common Is Residual Inflammatory Risk?
authors.affiliation: From the Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, MA; and the Harvard Medical School, Boston, MA. pridker@partners.org.
authors.forename: Paul M
authors.initials: PM
authors.lastname: Ridker
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000276:immunology; D015415:Biomarkers; D002097:C-Reactive Protein / Q000032:analysis; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D007249:Inflammation / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology*; D008074:Lipoproteins / Q000097:blood; D015337:Multicenter Studies as Topic; D000091362:PCSK9 Inhibitors; D012306:Risk; D057170:Translational Research, Biomedical; D000071449:Proprotein Convertase 9
chemical_list: D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D002097:C-Reactive Protein; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9
keywords: C-reactive protein; atherosclerosis; cholesterol; inflammation; prevention